Barinthus Biotherapeutics (BRNS) Earnings Date, Estimates & Call Transcripts $1.04 +0.12 (+12.68%) (As of 12/18/2024 05:45 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Barinthus Biotherapeutics Latest Earnings SummaryActual EPS (Nov. 6) -$0.21 Beat By $0.23 Consensus EPS (Nov. 6) -$0.44 Barinthus Biotherapeutics released Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.21, which topped the consensus estimate of -$0.44 by $0.23. Quarterly revenue was reported to be $14.97 million. With a trailing EPS of -$1.49, Barinthus Biotherapeutics' earnings are expected to decrease next year, from ($1.52) to ($1.85) per share. Get Barinthus Biotherapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Barinthus Biotherapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBRNS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BRNS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Barinthus Biotherapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.67-$0.59-$0.63Q2 20242-$0.54-$0.46-$0.50Q3 20242-$0.49-$0.48-$0.49Q4 20242-$0.49-$0.40-$0.45FY 20248-$2.19-$1.93-$2.06Q1 20252-$0.48-$0.37-$0.43Q2 20252-$0.48-$0.37-$0.43Q3 20252-$0.47-$0.39-$0.43Q4 20252-$0.47-$0.39-$0.43FY 20258($1.90)($1.52)($1.71) Barinthus Biotherapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/6/2024Q3 2024-$0.44-$0.21+$0.23-$0.21-$14.97M8/8/2024--$0.42-$0.43 -$0.01-$0.43--5/13/2024Q1 2024-$0.64-$0.40+$0.24-$0.40--3/20/2024Q4 2023-$0.55-$0.45+$0.10-$0.45--11/9/2023Q3 2023-$0.62-$0.37+$0.25-$0.37--8/10/2023Q2 2023-$0.59-$0.62 -$0.03-$0.62$0.65M$0.33M Get the Latest News and Ratings for BRNS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Barinthus Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/12/2023Q1 2023-$0.58-$0.48+$0.10-$0.48$1.12M$0.47M3/24/2023Q4 2022-$0.43-$0.55 -$0.12-$0.55$3.07M$6.46M Barinthus Biotherapeutics Earnings - Frequently Asked Questions When did Barinthus Biotherapeutics announce their last quarterly earnings? Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earning data on Wednesday, November 6, 2024. Learn more on BRNS's earnings history. Did Barinthus Biotherapeutics beat their earnings estimates last quarter? In the previous quarter, Barinthus Biotherapeutics (NASDAQ:BRNS) reported ($0.21) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.23. Learn more on analysts' earnings estimate vs. BRNS's actual earnings. How much revenue does Barinthus Biotherapeutics generate each year? Barinthus Biotherapeutics (NASDAQ:BRNS) has a recorded annual revenue of $14.97 million. How much profit does Barinthus Biotherapeutics generate each year? Barinthus Biotherapeutics (NASDAQ:BRNS) has a recorded net income of -$73.35 million. BRNS has generated -$1.49 earnings per share over the last four quarters. What is Barinthus Biotherapeutics's EPS forecast for next year? Barinthus Biotherapeutics's earnings are expected to decrease from ($1.52) per share to ($1.85) per share in the next year. More Earnings Resources from MarketBeat Related Companies Adaptimmune Therapeutics Earnings Puma Biotechnology Earnings Elutia Earnings Black Diamond Therapeutics Earnings Instil Bio Earnings Monopar Therapeutics Earnings Telomir Pharmaceuticals Earnings Compugen Earnings Galectin Therapeutics Earnings Atossa Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW This page (NASDAQ:BRNS) was last updated on 12/19/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
